sábado, 24 de noviembre de 2018

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. - PubMed - NCBI

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. - PubMed - NCBI



 2018 Nov 13;6(4). pii: E103. doi: 10.3390/diseases6040103.

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma.

Parkin A1Man J2Chou A3,4Nagrial AM5,6Samra J7Gill AJ8,9,10,11Timpson P12,13Pajic M14,15.

Abstract

Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapydepending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.

KEYWORDS:

clinical trials; molecular classification; pancreatic cancer; tailored therapy

PMID:
 
30428574
 
DOI:
 
10.3390/diseases6040103
Free full text

No hay comentarios: